Literature DB >> 28751773

Influence of IDH on FLT3-ITD status in newly diagnosed AML.

P Boddu1, K Takahashi1, N Pemmaraju1, N Daver1, C B Benton1, S Pierce1, M Konopleva1, F Ravandi1, J Cortes1, H Kantarjian1, C D DiNardo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28751773     DOI： 10.1038/leu.2017.244

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Authors:  H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

2.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

Authors:  D L Stirewalt; K J Kopecky; S Meshinchi; F R Appelbaum; M L Slovak; C L Willman; J P Radich
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

3.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

Authors:  Stefan Fröhling; Richard F Schlenk; Jochen Breitruck; Axel Benner; Sylvia Kreitmeier; Karen Tobis; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

6.  Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.

Authors:  Courtney D DiNardo; Farhad Ravandi; Sam Agresta; Marina Konopleva; Koichi Takahashi; Tapan Kadia; Mark Routbort; Keyur P Patel; Sherry Pierce; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2015-08       Impact factor: 13.265

7.  Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Authors:  Nicolas Boissel; Olivier Nibourel; Aline Renneville; Claude Gardin; Oumedaly Reman; Nathalie Contentin; Dominique Bordessoule; Cécile Pautas; Thierry de Revel; Bruno Quesnel; Pascal Huchette; Nathalie Philippe; Sandrine Geffroy; Christine Terre; Xavier Thomas; Sylvie Castaigne; Hervé Dombret; Claude Preudhomme
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 50.717

8.  Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.

Authors:  Keyur P Patel; Farhad Ravandi; Deqin Ma; Abhaya Paladugu; Bedia A Barkoh; L Jeffrey Medeiros; Rajyalakshmi Luthra
Journal:  Am J Clin Pathol       Date:  2011-01       Impact factor: 5.400

Review 9.  DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.

Authors:  A P Im; A R Sehgal; M P Carroll; B D Smith; A Tefferi; D E Johnson; M Boyiadzis
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 12.883

Review 10.  IDH mutations in acute myeloid leukemia.

Authors:  Dinesh Rakheja; Sergej Konoplev; L Jeffrey Medeiros; Weina Chen
Journal:  Hum Pathol       Date:  2012-08-20       Impact factor: 3.526
View more
  10 in total

1.  Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.

Authors:  Bingshan Liu; Roshni Narurkar; Madhura Hanmantgad; Wahib Zafar; Yongping Song; Delong Liu
Journal:  Front Med       Date:  2018-05-21       Impact factor: 4.592

2.  Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.

Authors:  Taylor Bucy; John M Zoscak; Motomi Mori; Uma Borate
Journal:  Blood Adv       Date:  2019-12-10

3.  Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies.

Authors:  Aditi Shastri; Jesus Gonzalez-Lugo; Amit Verma
Journal:  Blood Cancer Discov       Date:  2020-12-06

Review 4.  2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies.

Authors:  Vittoria Raimondi; Giulia Ciotti; Michele Gottardi; Francesco Ciccarese
Journal:  Biomedicines       Date:  2022-06-09

5.  Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.

Authors:  Peiting Zeng; Wenhua Lu; Jingyu Tian; Shuang Qiao; Jiangjiang Li; Christophe Glorieux; Shijun Wen; Hui Zhang; Yiqing Li; Peng Huang
Journal:  J Hematol Oncol       Date:  2022-03-21       Impact factor: 17.388

Review 6.  IDH1/2 mutations in acute myeloid leukemia.

Authors:  Ja Min Byun; Seung-Joo Yoo; Hyeong-Joon Kim; Jae-Sook Ahn; Youngil Koh; Jun Ho Jang; Sung-Soo Yoon
Journal:  Blood Res       Date:  2022-03-31

7.  IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis.

Authors:  Joerg Heineke; Michael Heuser; Badder Kattih; Amir Shirvani; Piroska Klement; Abel Martin Garrido; Razif Gabdoulline; Alessandro Liebich; Maximilian Brandes; Anuhar Chaturvedi; Timon Seeger; Felicitas Thol; Gudrun Göhring; Brigitte Schlegelberger; Robert Geffers; David John; Udo Bavendiek; Johann Bauersachs; Arnold Ganser
Journal:  Leukemia       Date:  2020-09-18       Impact factor: 12.883

8.  Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.

Authors:  Dong Chen; Siyuan Xia; Rukang Zhang; Yuancheng Li; Christopher A Famulare; Hao Fan; Rong Wu; Mei Wang; Allen C Zhu; Shannon E Elf; Rui Su; Lei Dong; Martha Arellano; William G Blum; Hui Mao; Sagar Lonial; Wendy Stock; Olatoyosi Odenike; Michelle Le Beau; Titus J Boggon; Chuan He; Jianjun Chen; Xue Gao; Ross L Levine; Jing Chen
Journal:  Mol Cell       Date:  2021-07-20       Impact factor: 19.328

Review 9.  Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Cancers (Basel)       Date:  2020-08-26       Impact factor: 6.639

10.  IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics.

Authors:  Yasser H ElNahass; Ragia H Badawy; Fatma A ElRefaey; Hend A Nooh; Dalia Ibrahiem; Heba A Nader; Hossam K Mahmoud; Wafaa H ElMetnawy
Journal:  Asian Pac J Cancer Prev       Date:  2020-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.